Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

DNA Mutations May Not Be the Cause of Cancer

DNA Mutations May Not Be the Cause of Cancer Cancer is the most challenging disease of our time with increasing numbers of new cases each year, worldwide. Great achievements have been reached in cancer research through deep sequencing which helped define druggable targets. However, the still-evolving targeted therapy suffers resistance suggesting that DNA mutations considered as drivers may not have a role in tumor initiation. The present work discusses the role of DNA mutations as drivers and passengers in cancer initiation and development. First, it is important to discern the role of these DNA mutations as initiating events causing cancer or as contributors crucial for the development of a tumor once it has initiated. Second, breast cancer shown here illustrates how identification of DNA mutations in cancerous cells has influenced our approach for anti-cancer drug design. The cancer trilogy we have reached and described as: initial drug; resistance/recurrence; drug/treatment combinations, calls for a paradigm shift. To design more effective cancer drugs with durable and positive outcome, future cancer research needs to move beyond the sequencing era and explore changes which are taking place in cancer cells at levels other than the DNA. Evolutionary constraints may be acting as a barrier to preserve the human species from being transformed and, for that matter, all multi-cellular species which can incur cancer. Furthermore, mutations in the DNA do occur and for a multitude of reasons but without necessarily causing cancer. New directions will draw themselves when more focus is given to the event responsible for the switch of a cell from normalcy to malignancy. Until then, targeted therapy will certainly continue to improve the outcome of patients; however, it is unlikely to eradicate breast cancer depicted here. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Oncology and Therapy Springer Journals

DNA Mutations May Not Be the Cause of Cancer

Adjiri, Adouda
Oncology and Therapy , Volume 5 (1) – May 15, 2017
Download PDF
17 pages

Loading next page...
 
/lp/springer-journals/dna-mutations-may-not-be-the-cause-of-cancer-4d1SoLdUpL
Publisher
Springer Journals
Copyright
Copyright © 2017 by The Author(s)
Subject
Medicine & Public Health; Internal Medicine
ISSN
2366-1070
eISSN
2366-1089
DOI
10.1007/s40487-017-0047-1
Publisher site
See Article on Publisher Site

Abstract

Cancer is the most challenging disease of our time with increasing numbers of new cases each year, worldwide. Great achievements have been reached in cancer research through deep sequencing which helped define druggable targets. However, the still-evolving targeted therapy suffers resistance suggesting that DNA mutations considered as drivers may not have a role in tumor initiation. The present work discusses the role of DNA mutations as drivers and passengers in cancer initiation and development. First, it is important to discern the role of these DNA mutations as initiating events causing cancer or as contributors crucial for the development of a tumor once it has initiated. Second, breast cancer shown here illustrates how identification of DNA mutations in cancerous cells has influenced our approach for anti-cancer drug design. The cancer trilogy we have reached and described as: initial drug; resistance/recurrence; drug/treatment combinations, calls for a paradigm shift. To design more effective cancer drugs with durable and positive outcome, future cancer research needs to move beyond the sequencing era and explore changes which are taking place in cancer cells at levels other than the DNA. Evolutionary constraints may be acting as a barrier to preserve the human species from being transformed and, for that matter, all multi-cellular species which can incur cancer. Furthermore, mutations in the DNA do occur and for a multitude of reasons but without necessarily causing cancer. New directions will draw themselves when more focus is given to the event responsible for the switch of a cell from normalcy to malignancy. Until then, targeted therapy will certainly continue to improve the outcome of patients; however, it is unlikely to eradicate breast cancer depicted here.

Journal

Oncology and Therapy – Springer Journals

Published: May 15, 2017

References

  • A review of 2014 cancer drug approvals, with a look at 2015 and beyond
    Butler, T; Maravent, S; Boisselle, J
  • Drug resistance in cancer: an overview
    Housman, G; Byler, S; Heerboth, S
  • Weighted gene co-expression network analysis in identification of metastasis-related genes of lung squamous cell carcinoma based on the Cancer Genome Atlas database
    Tian, F; Zhao, J; Fan, X
  • Analysis of the cancer genome atlas sequencing data reveals novel properties of the human papillomavirus 16 genome in head and neck squamous cell carcinoma
    Nulton, TJ; Olex, AL; Dozmorov, M
  • Unraveling the genetics of cancer: genome sequencing and beyond
    Wong, KM; Hudson, TJ; McPherson, JD
  • A census of human cancer genes
    Futreal, PA; Lachlan, C; Mhairi, M
  • The genomic landscapes of human breast and colorectal cancers
    Wood, LD; Parsons, DW; Jones, S
  • Passenger deletions generate therapeutic vulnerabilities in cancer
    Muller, FL; Colla, S; Aquilanti, E
  • A comprehensive catalogue of somatic mutations from a human cancer genome
    Pleasance, ED; Cheetham, RK; Stephens, PJ
  • Patterns of somatic mutation in human cancer genomes
    Greenman, C; Stephens, P; Smith, R
  • Cancer genome landscapes
    Vogelstein, B; Papadopoulos, N; Velculescu, VE
  • The cancer genome
    Straton, MR; Campbell, PJ; Futreal, PA
  • Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors
    Jones, SJM; Laskin, J; Li, YY
  • Personalized oncology through integrative high-throughput sequencing: a pilot study
    Roychowdhury, S; Iyer, MK; Robinson, DR
  • Crizotinib versus chemotherapy in advanced ALK-positive lung cancer
    Shaw, AT; Kim, DW; Nakagawa, K
  • Targeting HER1/EGFR: a molecular approach to cancer therapy
    Arteaga, C
  • Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib therapy
    Lynch, TJ; Bell, DW; Sordella, R
  • Three generations of epidermal growth factor receptor tyrosine kinase inhibitors developed to revolutionize the therapy of lung cancer
    Zhang, H
  • EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
    Kobayashi, S; Boggon, TJ; Dayaram, T
  • Mechanisms of acquired resistance to AZD9291 in EGFR T790M positive lung cancer
    Oxnard, GR; Thress, K; Paweletz, C
  • The consensus coding sequences of human breast and colorectal cancers
    Sjöblom, T; Jones, S; Wood, LD
  • Exome sequencing identifies GRIN2A as frequently mutated in melanoma
    Wei, X; Walia, V; Lin, JC
  • A landscape of driver mutations in melanoma
    Hodis, E; Watson, IR; Kryukov, GV
  • Melanoma genome sequencing reveals frequent PREX2 mutations
    Berger, MF; Hodis, E; Heffernan, TP
  • Clonal Architectures and driver mutations in metastatic melanomas
    Ding, L; Kim, M; Kanchi, KL
  • Analysis of the genome to personalize therapy for melanoma
    Davies, MA; Samuels, Y
  • The role of BRAF mutations in primary melanoma growth rate and survival
    Mar, VJ; Liu, W; Devitt, B
  • BRAF mutations are common somatic events in melanocytic nevi
    Kumar, R; Angelini, S; Snellman, E
  • Clonal BRAF mutations in melanocytic nevi and initiating role of BRAF in melanocytic neoplasia
    Yeh, I; Deimling, A; Bastian, BC
  • Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer
    Wang, K; Yuen, ST; Xu, J
  • Identifying and targeting the cause of cancer is needed to cure cancer
    Adjiri, A
  • Genetic progression and the waiting time to cancer
    Beerenwinkel, N; Antal, T; Dingli, D
  • Frequent engagement of the classical and alternative NF-κB pathways by diverse genetic abnormalities in multiple myeloma
    Annunziata, CM; Davis, RE; Demchenko, Y
  • Promiscuous mutations activate the non-canonical NF-kB pathway in multiple myeloma
    Keats, JJ; Fonseca, R; Chesi, M
  • Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic keratoses with a characteristic mutation pattern
    Hafner, C; López-Knowles, E; Luis, NM
  • High frequency of BRAF mutations in nevi
    Pollock, PM; Harper, UL; Hansen, KS
  • Congenital melanocytic nevi frequently harbor NRAS mutations but no BRAF mutations
    Bauer, J; Curtin, JA; Pinkel, D
  • BRAF and NRAS mutations in melanoma and melanocytic nevi
    Poynter, JN; Elder, JT; Fullen, DR
  • Co-existence of BRAF and NRAS driver mutations in the same melanoma cells results in heterogeneity of targeted therapy resistance
    Raaijmakers, MIG; Widmer, DS; Narechania, A
  • The specificity of p53 mutation spectra in sunlight induced human cancers
    Daya-Grosjean, L; Dumaz, N; Sarasin, A
  • The role of UV induced lesions in skin carcinogenesis: an overview of oncogene and tumor suppressor gene modifications in xeroderma pigmentosum skin tumors
    Daya-Grosjean, L; Sarasin, A
  • Peto’s paradox and the hallmarks of cancer: constructing an evolutionary framework for understanding the incidence of cancer
    Nunney, L; Muir, B
  • BRCA1 mutations in primary breast and ovarian carcinomas
    Futreal, PA; Liu, Q; Shattuck-Eidens, D
  • BRCA2 mutations in primary breast and ovarian cancers
    Lancaster, JM; Wooster, R; Mangion, J
  • Li–Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype
    Olivier, M; Goldgar, DE; Sodha, N
  • Mutations of the p53 tumour suppressor gene in erosive rheumatoid synovial tissue
    Rème, T; Travaglio, A; Gueydon, E
  • Somatic mutations in the p53 tumor suppressor gene in rheumatoid arthritis synovium
    Firestein, GS; Echeverri, F; Yeo, M
  • Li–Fraumeni syndrome
    Malkin, D
  • Human cancer syndromes: clues to the origin and nature of cancer
    Fearon, ER
  • Merotelic kinetochore orientation, aneuploidy, and cancer
    Cimini, D
  • Does aneuploidy cause cancer?
    Weaver, BA; Cleveland, DW
  • Mitotic chromosomal instability and cancer: mouse modeling of the human disease
    Schvartzman, JM; Sotillo, R; Benezra, R
  • Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions
    Gorgoulis, VG; Vassiliou, LV; Karakaidos, P
  • Genetic instability in colorectal cancers
    Lengauer, C; Kinzler, KW; Vogelstein, B
  • Cytokinesis failure generating tetraploids promotes tumorigenesis in p53-null cells
    Fujiwara, T; Bandi, M; Nitta, M
  • Aneuploidy acts both oncogenically and as a tumor suppressor
    Weaver, BA; Silk, AD; Montagna, C
  • Chromosome missegregation rate predicts whether aneuploidy will promote or suppress tumors
    Silk, AD; Zasadil, LM; Holland, AJ
  • Incidence and spectrum of chromosome abnormalities in spontaneous abortions: new insights from a 12-year study
    Menasha, J; Levy, B; Hirschhorn, K
  • Cancer: a disease at the crossroads of trade-offs
    Jacqueline, C; Biro, PA; Beckmann, C
  • Constraints in cancer evolution
    Venkatesan, S; Birkbak, NJ; Swanton, C
  • Intratumor heterogeneity and branched evolution revealed by multiregion sequencing
    Gerlinger, M; Rowan, AJ; Horswell, S
  • Intratumor heterogeneity: seeing the wood for the trees
    Yap, TA; Gerlinger, M; Futreal, PA
  • Intratumour heterogeneity: evolution through space and time
    Swanton, C
  • Translational implications of tumor heterogeneity
    Jamal-Hanjani, M; Quezada, SA; Larkin, J
  • Inferring mutational timing and reconstructing tumour evolutionary histories
    Turajlic, S; McGranahan, N; Swanton, C
  • Comprehensive genomic characterization defines human glioblastoma genes and core pathways
    McLendon, R; Friedman, A; Bigner, D
  • Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing
    Ding, L; Ley, TJ; Larson, DE
  • Evolutionary dynamics of carcinogenesis and why targeted therapy does not work
    Gillies, RJ; Verduzco, D; Gatenby, RA
  • Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution
    Shah, SP; Morin, RD; Khattra, J
  • Cell culture system for analysis of genetic heterogeneity within hepatocellular carcinomas and response to pharmacologic agents
    Gao, Q; Wang, ZC; Duan, M
  • Intratumor heterogeneity in hepatocellular carcinoma
    Friemel, J; Rechsteiner, M; Frick, L
  • Effects of age on the detection and management of breast cancer
    McGuire, A; Brown, JA; Malone, C
  • Histological types of breast cancer: how special are they?
    Weigelt, B; Geyer, FC; Reis-Filho, JS
  • Androgen receptor: a complex therapeutic target for breast cancer
    Narayanan, R; Dalton, JT
  • Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
    Slamon, DJ; Godolphin, W; Jones, LA; Holt, JA; Wong, SG; Keith, DE
  • Expression of the erbb-2 family of growth factor receptors and their ligands in breast cancers. Implication for tumor biology and clinical behavior
    Bacus, SS; Zelnick, CR; Plowman, G; Yarden, Y
  • HER-2 signaling and inhibition in breast cancer
    Browne, BC; O’Brien, N; Duffy, MJ; Crown, J; O’Donovan, N
  • Adjuvant trastuzumab in HER2-positive breast cancer
    Slamon, D; Eiermann, W; Robert, N
  • Trastuzumab in the adjuvant treatment of HER2-positive early breast cancer patients: a meta-analysis of published randomized controlled trials
    Yin, W; Jiang, Y; Shen, Z
  • Original report: 4-year follow- up of trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSAB B-31
    Perez, EA; Romond, EH; Suman, VJ
  • Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
    Romond, EH; Perez, EA; Bryant, J
  • Trastuzumab: updated mechanisms of action and resistance in breast cancer
    Vu, T; Claret, FX
  • Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy
    Baselga, J; Gelmon, KA; Verma, S
  • The european medicines agency review of pertuzumab for the treatment of adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer: summary of the scientific assessment of the committee for medicinal products for human use
    Boix-Perales, H; Borregaard, J; Jensen, KB
  • Role of pertuzumab in the treatment of HER2-positive breast cancer
    Hubalek, M; Brantner, C; Marth, C
  • Dual HER2-targeted approaches in HER2-positive breast cancer
    Ahn, ER; Vogel, CL
  • Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
    Piccart-Gebhart, MJ; Procter, M; Leyland-Jones, B
  • First results from the phase III ALTTO trial (BIG 2-06; NCCTG [alliance] N063D) comparing 1 year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T → L), or their combination (T + L) in the adjuvant treatment of HER2-positive early breast cancer (EBC)
    Piccart-Gebhart, MJ; Holmes, AP; Baselga, J
  • Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer
    Baselga, J
  • Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway
    Nahta, R; O’Regan, RM
  • Inhibition of mammalian target of rapamycin is required for optimal antitumor effect of HER2 inhibitors against HER2-overexpressing cancer cells
    Miller, TW; Forbes, JT; Shah, C
  • The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers
    Paplomata, E; O’Regan, R
  • PI3K/Akt/mTOR inhibitors in breast cancer
    Lee, JJX; Loh, K; Yap, YS
  • Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells
    Konecny, GE; Pegram, MD; Venkatesan, N
  • Small molecule tyrosine kinase inhibitors of ErbB2/HER2/Neu in the treatment of aggressive breast cancer
    Schroeder, RL; Stevens, CL; Sridhar, J
  • An update on PARP inhibitors for the treatment of cancer
    Benafif, S; Hall, M
  • Overview of resistance to systemic therapy in patients with breast cancer
    Gonzalez-Angulo, AM; Morales-Vasquez, F; Hortobagyi, GN
  • Mutational processes molding the genomes of 21 breast cancers
    Nik-Zainal, S; Alexandrov, LB; Wedge, DC
  • Targeting DNA repair pathways for cancer treatment: what’s new?
    Kelley, MR; Logsdon, D; Fishel, ML
  • Somatic BRCA1/2 recovery as a resistance mechanism after exceptional response to poly (ADP-ribose) polymerase inhibition
    Lheureux, S; Bruce, JP; Burnier, JV
  • Gemcitabine mono-therapy versus gemcitabine plus targeted therapy in advanced pancreatic cancer: a meta-analysis of randomized phase III trials
    Ottaiano, A; Capozzi, M; Divitiis, C
  • Tumor microenvironment and differential responses to therapy
    Hirata, E; Sahai, E
  • Hallmarks of cancer: the next generation
    Hanahan, D; Weinberg, RA
  • Intra-tumour heterogeneity—going beyond genetics
    Caiado, F; Silva-Santos, B; Norell, H